Breaking News, Promotions & Moves

Amgen

Robert A. Bradway has been appointed president and chief operating officer of Amgen, effective May 11.

Robert A. Bradway has been appointed president and chief operating officer of Amgen, effective May 11. Mr. Bradway will be responsible for the company’s Global Commercial Operations, Manufacturing Operations, Strategy and Corporate Development, Information Technology, Global Government Affairs and Compliance. He will report to Kevin Sharer, Amgen’s chairman and chief executive officer.

Mr. Bradway has served as the company’s executive vice president and chief financial officer since April 2007. He joined the company in 2006 as vice president, Operations Strategy. Prior to joining the company, he was a managing director at Morgan Stanley in London, where he was responsible for the firm’s banking department and corporate finance activities in Europe.

Also, George J. Morrow, executive vice president of Global Commercial Operations, will retire effective January 31, 2011. Mr. Morrow will report to Mr. Sharer until his retirement and will be involved in the preparations for the company’s launch of Prolia (denosumab) as well as other strategic projects.

“Bob Bradway is an outstanding executive with significant potential. He earned it,” Mr. Sharer said.”We note with deep appreciation and respect the exceptional accomplishment and contribution of George Morrow to the success of Amgen during the last decade. George will be focused on the success of Prolia worldwide for the balance of the year and will work with Bob and I on strategic initiatives and public policy. The new commercial leadership team that will report to Bob and take over day-to-day responsibility from George is seasoned and ready.”

Also effective May 11, Michael A. Kelly, Amgen’s vice president of finance and chief accounting officer, will serve as acting chief financial officer. Mr. Kelly joined Amgen in 2003 and has served as chief accounting officer since 2005.

“Michael Kelly is an able and experienced financial executive who will be the interim CFO reporting to me as we conduct an external search for a permanent CFO,” Mr. Sharer noted.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters